<DOC>
	<DOCNO>NCT02259127</DOCNO>
	<brief_summary>A new anti-HIV medicine ( Dolutegravir ) combine 2 currently use anti-HIV medicine non-inferior standard combination medicine use term efficacy good term toxicity .</brief_summary>
	<brief_title>A Randomised Trial Dolutegravir ( DTG ) -Based Antiretroviral Therapy vs. Standard Care ( SOC ) Children With HIV Infection Starting First-line Switching Second-line ART</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>ALL PATIENTS : Children &lt; 18 year confirm HIV1 infection DTG dose know child 's age/weightband Parents/carers child , applicable , give inform write consent Girls age 12 year old reach menses must negative pregnancy test screen willing adhere effective method contraception sexually active Children coinfections need start ART enrol ODYSSEY accord local/national guideline Parents/carers child , applicable , willing adhere minimum 96 week ' followup Recruitment start child age ≥6 &lt; 18 year dose information formulation currently available . Additional formulation young child become available trial dose information update . ADDITIONAL CRITERIA FOR ODYSSEY A : • Planning start firstline ART ADDITIONAL CRITERIA FOR ODYSSEY B : Planning start secondline ART define switch least 2 ART drug due treatment failure Treated one previous ART regimen At least one NRTI predict preserved activity available background regimen In setting resistance test routinely available , least one new active NRTI tenofovir disoproxil fumarate , abacavir zidovudine preserve activity base cumulative result resistance test within 3 month In setting resistance test routinely available , child due switch accord national guideline least one new NRTI predict available tenofovir disoproxil fumarate , abacavir zidovudine Viral load &gt; 1000 c/ml screen visit History presence know allergy contraindication study drug component Alanine aminotransferase ( ALT ) ≥ 5 time upper limit normal , OR ALT ≥3x upper limit normal bilirubin ≥1.5x upper limit normal Patients severe hepatic impairment unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , oesophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Anticipated need Hepatitis C virus ( HCV ) therapy study Pregnancy breastfeed Evidence lack susceptibility integrase inhibitor 2week exposure antiretrovirals class Contraindications propose available NRTI backbone</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>